Don Kiepert, BS 1971 & MS 1973
Executive Chairman, CEO, and Board Member
Don has been a successful entrepreneur who has started and led twelve successful healthcare companies.
He has chaired and served on multiple healthcare company boards in the home infusion, biopharmaceutical, medical device and radiopharmaceutical industries.
He has worked extensively with PE firms in completing diligence on the acquisition of three companies. He has advised multiple PE firms in evaluating assets to be acquired.
Most recently he collaborated with CapVest, a London based PE firm, in assisting with the diligence on the acquisition of IBA Molecular and Mallinckrodt Nuclear Medicine. The company created is Curium Pharma, the global leading radiopharmaceutical company. Besides assisting on the M and A process he provides advisory support on compliance, organizational development and licensing opportunities.
Don previously spent fifteen years in the home infusion industry. He started Chartwell Home Therapies which became the leading company in creating home infusion services partnerships with academic medical centers. The company launched 20 sites and partnered with 22 Academic Medical Centers. Part of Chartwell's strategy included specialty pharmacy capabilities which fully leveraged the relationships with the AMCs. The company was sold to a PE firm.
In 2014 and 2015 Don spent fifteen months as an full time advisor to Bain Capital assisting in developing the optimal strategy for the launching of their 503B company QuVa. During that time frame he developed a full business plan for Touchstone Pharmacy Services, a planned company in the 503B space.
He assisted Avista Capital, a NYC based PE firm in the diligence on BMS Medical Imaging and once acquired became CEO of Lantheus Medical Imaging, an Avista owned company, which was a global provider of nine imaging products and was developing three pipeline assets.
Prior to Lantheus, Don founded Point Therapeutics, which was developing immunotherapy agents for treating cancer patients. Under Don's leadership the company went public and raised $100 M in capital to clinically advance the technology.
Don recently founded Seropeutics, LLC an early stage biopharmaceutical company that will develop drugs for various neurological diseases.
Early in Don's career he held multiple senior manager positions at Baxter Travenol, including co-founding the Travacare Division which became the industry leading home infusion company.
Current board roles include Curium Pharma, the global leading radio pharmaceutical company, Lucerno Dynamics, a medical device company, Ethismos, a biotechnology company, Multiverse Health, an early stage medical device company, and Terran Biosciences, the leading company in the psilocybin space. He also serves as a board advisor to Reiley Pharmaceuticals, and Bach Biosciences.
He is a pharmacist with an advanced degree in clinical pharmacy, and lives in New Hampshire